Biomarkers Market by Product (Consumables, Services), Type (Predictive, Pharmacodynamic, Safety), Application (Diagnostics, Drug Discovery, Personalized Medicine) & by Disease Indication (Cardiovascular, Immunological) - Global Forecast to 2020

Date: July 17, 2015
Pages: 182
Price:
US$ 5,650.00
License [?]:
Publisher: MarketsandMarkets
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: B716B1E86B3EN
Leaflet:

Download PDF Leaflet

Biomarkers Market by Product (Consumables, Services), Type (Predictive, Pharmacodynamic, Safety), Application (Diagnostics, Drug Discovery, Personalized Medicine) & by Disease Indication (Cardiovascular, Immunological) - Global Forecast to 2020
In this report, the biomarkers market is segmented on the basis of product, type, application, disease indication, and geography. The product segments included in this report are consumables, services, software. The type segments included in this report are safety biomarkers, efficacy biomarkers, and validation biomarkers. The applications segments included in this report are diagnostics development, drug discovery and development, personalized medicine, disease risk assessment, and other applications. The disease indications segments included in this report are cancer, cardiovascular disorders, neurological disorders, immunological disorders, and other diseases.

The geographic segments included in this report are North America, Europe, Asia, and the Rest of the World (RoW).

The growth of this market is mainly driven by increasing healthcare expenditure, increase in R&D spending, increasing utility of biomarkers for diagnostics, increasing number of CROs, the low cost of clinical trials in developing countries, and new initiatives for biomarker research. The high growth potential in emerging markets and the increasing adoption of personalized medicine and companion diagnostics provides new growth opportunities to players in the biomarkers market.

A combination of bottom-up and top-down approaches were used to calculate the market sizes and growth rates of the global biomarkers market and its subsegments. Secondary information was used to identify overall revenue, geographic reach, and product portfolios of market players. Estimates of the biomarkers market segment revenues were validated through primary interviews. Primary interviews with key opinion leaders were also used to determine the percentage shares of each subsegment and the relative differences in growth rates.

The report provides qualitative insights on key market shares, growth rates, and market drivers for important subsegments. It maps the market sizes and growth rates of each segment and identifies segments poised to witness rapid growth. The report includes company profiles and a competitive landscape of the biomarkers market. The company profiles include the financial performances, product portfolios, and developments of each company, whereas, the competitive landscape covers the growth strategies adopted by industry players over the last three years. The report also includes analyses of industry developments such as acquisitions, agreements, collaborations & partnerships; new product launches; and other developments.

Reasons to Buy the Report:

The report will enable both established firms and new entrants to gauge the pulse of the market and make important strategic growth decisions.

The report provides insights on the following:
  • Product Development/Innovation: Product portfolios of the top players in the biomarkers market. Detailed insights on upcoming technologies, R&D activities, and new product launches in the biomarkers market
  • Competitive Assessment: In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of the leading players in the biomarkers market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various biomarkers across geographies
  • Market Diversification: Exhaustive information about new products, recent developments, and investments in the biomarkers market
1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
  1.3.1 MARKETS COVERED
  1.3.2 YEARS CONSIDERED IN THE REPORT
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

2.1 MARKET SIZE ESTIMATION
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.3 MARKET SHARE ESTIMATION
  2.3.1 KEY DATA FROM SECONDARY SOURCES
  2.3.2 KEY DATA FROM PRIMARY SOURCES
  2.3.3 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 LUCRATIVE OPPORTUNITIES IN THE GLOBAL BIOMARKERS MARKET
4.2 LIFE CYCLE ANALYSIS, BY REGION, 2015

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET SEGMENTATION
  5.2.1 BY PRODUCT
  5.2.2 BY TYPE
  5.2.3 BY APPLICATION
  5.2.4 BY DISEASE INDICATION
5.3 MARKET DYNAMICS
  5.3.1 DRIVERS
    5.3.1.1 Increasing healthcare expenditure
    5.3.1.2 Growth in R&D funding
    5.3.1.3 Increasing utility of biomarkers for diagnostic purposes
    5.3.1.4 Rising number of CROs and low cost for conducting clinical trials in developing countries
    5.3.1.5 High prevalence of cancer
    5.3.1.6 New initiatives for biomarker research
  5.3.2 RESTRAINTS
    5.3.2.1 High capital investment and low benefit-cost ratio
    5.3.2.2 Poorly suited regulatory and reimbursement systems
    5.3.2.3 High cost of tests
    5.3.2.4 Technical issues related to sample collection and storage
  5.3.3 OPPORTUNITIES
    5.3.3.1 Personalized medicine
    5.3.3.2 Companion diagnostics
    5.3.3.3 Emerging economies
  5.3.4 CHALLENGES
    5.3.4.1 Proving clinical validity and utility of biomarker-based tests

6 BIOMARKERS MARKET, BY PRODUCTS

6.1 INTRODUCTION
6.2 CONSUMABLES
6.3 SERVICES
6.4 SOFTWARE

7 BIOMARKERS MARKET, BY TYPE

7.1 INTRODUCTION
7.2 SAFETY BIOMARKERS
7.3 EFFICACY BIOMARKERS
  7.3.1 PREDICTIVE BIOMARKERS
  7.3.2 SURROGATE BIOMARKERS
  7.3.3 PHARMACODYNAMIC BIOMARKERS
  7.3.4 PROGNOSTIC BIOMARKERS
7.4 VALIDATION BIOMARKERS

8 BIOMARKERS MARKET, BY APPLICATION

8.1 INTRODUCTION
8.2 DIAGNOSTICS DEVELOPMENT
8.3 DRUG DISCOVERY AND DEVELOPMENT
8.4 PERSONALIZED MEDICINE
8.5 DISEASE RISK ASSESSMENT
8.6 OTHER APPLICATIONS

9 BIOMARKERS MARKET, BY DISEASE INDICATION

9.1 INTRODUCTION
9.2 CANCER
9.3 CARDIOVASCULAR DISORDERS
9.4 NEUROLOGICAL DISORDERS
9.5 IMMUNOLOGICAL DISORDERS
9.6 OTHER DISEASES

10 BIOMARKERS MARKET, BY REGION

10.1 INTRODUCTION
10.2 NORTH AMERICA
  10.2.1 U.S.
  10.2.2 CANADA
10.3 EUROPE
10.4 ASIA
10.5 REST OF THE WORLD (ROW)

11 COMPETITIVE LANDSCAPE

11.1 INTRODUCTION
11.2 STRATEGIC OVERVIEW
11.3 MARKET SHARE ANALYSIS, BIOMARKERS MARKET
11.4 COMPETITIVE SITUATION AND TRENDS
  11.4.1 ACQUISITIONS
  11.4.2 AGREEMENTS, COLLABORATIONS, EXPANSION, JOINT VENTURES, AND PARTNERSHIPS
  11.4.3 NEW PRODUCT AND SERVICE LAUNCHES
  11.4.4 OTHER DEVELOPMENTS

12 COMPANY PROFILES

(Overview, Financials, Products & Services, Strategy, & Developments)*

12.1 INTRODUCTION
12.2 QIAGEN N.V.
12.3 PERKINELMER, INC.
12.4 MERCK & CO, INC.
12.5 BIO-RAD LABORATORIES, INC.
12.6 ENZO BIOCHEM, INC.
12.7 EKF DIAGNOSTICS HOLDINGS, INC.
12.8 MESO SCALE DIAGNOSTICS, LLC.
12.9 SINGULEX, INC.
12.10 BIOSIMS TECHNOLOGIES
12.11 CISBIO BIOASSAYS
12.12 SIGNOSIS, INC.

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

13 APPENDIX

13.1 INSIGHTS OF INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 OTHER DEVELOPMENTS
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
13.5 AVAILABLE CUSTOMIZATIONS
13.6 RELATED REPORTS

LIST OF TABLES

Table 1 BIOMARKERS MARKET SNAPSHOT
Table 2 INCREASING HEALTHCARE EXPENDITURE IS PROPELLING THE GROWTH OF BIOMARKERS MARKET
Table 3 POORLY SUITED REGULATORY AND REIMBURSEMENT SYSTEMS—AN ENTRY BARRIER FOR NEW ENTRANTS
Table 4 LIST OF FDA-APPROVED BIOMARKERS FOR DIFFERENT TYPES OF CANCER
Table 5 EMERGING ECONOMIES PRESENT SIGNIFICANT GROWTH OPPORTUNITIES
Table 6 PROVING THE CLINICAL VALIDITY & UTILITY OF BIOMARKER-BASED TESTS IS A MAJOR CHALLENGE FOR MARKET PLAYERS
Table 7 BIOMARKERS MARKET SIZE, BY PRODUCT, 2013–2020 ($BILLION)
Table 8 BIOMARKER CONSUMABLES MARKET, BY REGION, 2013–2020 ($BILLION)
Table 9 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY REGION, 2013–2020 ($BILLION)
Table 10 BIOMARKER SERVICES MARKET, BY REGION, 2013–2020 ($BILLION)
Table 11 NORTH AMERICA: BIOMARKER SERVICES MARKET, BY REGION, 2013–2020 ($BILLION)
Table 12 BIOMARKER SOFTWARE MARKET, BY REGION, 2013–2020 ($BILLION)
Table 13 NORTH AMERICA: BIOMARKER SOFTWARE MARKET, BY REGION, 2013–2020 ($MILLION)
Table 14 BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 ($BILLION)
Table 15 SAFETY BIOMARKERS MARKET SIZE, BY REGION, 2013–2020 ($BILLION)
Table 16 NORTH AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2013–2020 ($BILLION)
Table 17 EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 ($BILLION)
Table 18 EFFICACY BIOMARKERS MARKET SIZE, BY REGION, 2013–2020 ($BILLION)
Table 19 NORTH AMERICA: EFFICACY BIOMARKERS MARKET SIZE, BY COUNTRY, 2013–2020 ($BILLION)
Table 20 PREDICTIVE BIOMARKERS MARKET SIZE, BY REGION, 2013–2020 ($BILLION)
Table 21 NORTH AMERICA: PREDICTIVE BIOMARKERS MARKET SIZE, BY COUNTRY, 2013–2020 ($MILLION)
Table 22 SURROGATE BIOMARKERS MARKET SIZE, BY REGION, 2013–2020 ($BILLION)
Table 23 NORTH AMERICA: SURROGATE BIOMARKERS MARKET SIZE, BY COUNTRY, 2013–2020 ($BILLION)
Table 24 PHARMACODYNAMIC BIOMARKERS MARKET SIZE, BY REGION, 2013–2020 ($BILLION)
Table 25 NORTH AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2013–2020 ($BILLION)
Table 26 PROGNOSTIC BIOMARKERS MARKET SIZE, BY REGION, 2013–2020 ($BILLION)
Table 27 NORTH AMERICA: PROGNOSTIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2013–2020 ($BILLION)
Table 28 VALIDATION BIOMARKERS MARKET SIZE, BY REGION, 2013–2020 ($BILLION)
Table 29 NORTH AMERICA: VALIDATION BIOMARKERS MARKET SIZE, BY COUNTRY, 2013–2020 ($BILLION)
Table 30 BIOMARKERS MARKET SIZE, BY APPLICATION, 2013–2020 ($BILLION)
Table 31 DIAGNOSTICS DEVELOPMENT MARKET SIZE, BY REGION, 2013–2020 ($BILLION)
Table 32 NORTH AMERICA: DIAGNOSTICS DEVELOPMENT MARKET SIZE, BY COUNTRY, 2013–2020 ($BILLION)
Table 33 DRUG DISCOVERY AND DEVELOPMENT MARKET SIZE, BY REGION, 2013–2020 ($BILLION)
Table 34 NORTH AMERICA: DRUG DISCOVERY AND DEVELOPMENT MARKET SIZE, BY COUNTRY, 2013–2020 ($BILLION)
Table 35 PERSONALIZED MEDICINE MARKET SIZE, BY REGION, 2013–2020 ($BILLION)
Table 36 NORTH AMERICA: PERSONALIZED MEDICINE MARKET SIZE, BY COUNTRY, 2013–2020 ($BILLION)
Table 37 DISEASE RISK ASSESSMENT MARKET SIZE, BY REGION, 2013–2020 ($BILLION)
Table 38 NORTH AMERICA: DISEASE RISK ASSESSMENT MARKET SIZE, BY COUNTRY, 2013–2020 ($BILLION)
Table 39 BIOMARKERS MARKET SIZE FOR OTHER APPLICATIONS, BY REGION, 2013–2020 ($BILLION)
Table 40 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR OTHER APPLICATIONS, BY COUNTRY, 2013–2020 ($BILLION)
Table 41 BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2013–2020 ($BILLION)
Table 42 KEY CANCER BIOMARKERS IN CLINICAL USE
Table 43 ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT FOR THE CANCER DISEASE INDICATION SEGMENT
Table 44 BIOMARKERS MARKET SIZE FOR CANCER, BY REGION, 2013–2020 ($BILLION)
Table 45 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR CANCER, BY REGION, 2013–2020 ($BILLION)
Table 46 CARDIOVASCULAR DISORDER BIOMARKERS
Table 47 BIOMARKERS MARKET SIZE FOR CARDIOVASCULAR DISORDERS, BY REGION, 2013–2020 ($BILLION)
Table 48 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR CARDIOVASCULAR DISORDERS, BY REGION, 2013–2020 ($BILLION)
Table 49 BIOMARKERS MARKET SIZE FOR NEUROLOGICAL DISORDERS, BY REGION, 2013–2020 ($BILLION)
Table 50 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR NEUROLOGICAL DISORDERS, BY REGION, 2013–2020 ($BILLION)
Table 51 BIOMARKERS FOR IMMUNOLOGICAL DISEASES
Table 52 BIOMARKERS MARKET SIZE FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2013–2020 ($BILLION)
Table 53 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2013–2020 ($BILLION)
Table 54 BIOMARKERS FOR RENAL DISORDERS
Table 55 BIOMARKERS MARKET SIZE FOR OTHER DISEASE INDICATIONS, BY REGION, 2013–2020 ($BILLION)
Table 56 NORTH AMERICA: BIOMARKERS MARKET SIZE FOR OTHER DISEASE INDICATIONS, BY REGION, 2013–2020 ($BILLION)
Table 57 BIOMARKERS MARKET SIZE, BY REGION, 2013–2020 ($BILLION)
Table 58 NORTH AMERICA: BIOMARKERS MARKET SIZE, BY COUNTRY, 2013–2020 ($BILLION)
Table 59 NORTH AMERICA: BIOMARKERS MARKET SIZE, BY PRODUCT, 2013–2020 ($BILLION)
Table 60 NORTH AMERICA: BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 ($BILLION)
Table 61 NORTH AMERICA: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 ($BILLION)
Table 62 NORTH AMERICA: BIOMARKERS MARKET SIZE, BY APPLICATION, 2013–2020 ($BILLION)
Table 63 NORTH AMERICA: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2013–2020 ($BILLION)
Table 64 U.S.: BIOMARKERS MARKET SIZE, BY PRODUCT, 2013–2020 ($BILLION)
Table 65 U.S.: BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 ($BILLION)
Table 66 U.S.: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 ($BILLION)
Table 67 U.S.: BIOMARKERS MARKET SIZE, BY APPLICATION, 2013–2020 ($BILLION)
Table 68 U.S.: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2013–2020 ($BILLION)
Table 69 CANADA: BIOMARKERS MARKET SIZE, BY PRODUCT, 2013–2020 ($BILLION)
Table 70 CANADA: BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 ($BILLION)
Table 71 CANADA: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 ($BILLION)
Table 72 CANADA: BIOMARKERS MARKET SIZE, BY APPLICATION, 2013–2020 ($BILLION)
Table 73 CANADA: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2013–2020 ($BILLION)
Table 74 EUROPE: BIOMARKERS MARKET SIZE, BY PRODUCT, 2013–2020 ($BILLION)
Table 75 EUROPE: BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 ($BILLION)
Table 76 EUROPE: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 ($BILLION)
Table 77 EUROPE: BIOMARKERS MARKET SIZE, BY APPLICATION, 2013–2020 ($BILLION)
Table 78 EUROPE: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2013–2020 ($BILLION)
Table 79 ASIA: BIOMARKERS MARKET SIZE, BY PRODUCT, 2013–2020 ($BILLION)
Table 80 ASIA: BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 ($BILLION)
Table 81 ASIA: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 ($BILLION)
Table 82 ASIA: BIOMARKERS MARKET SIZE, BY APPLICATION, 2013–2020 ($BILLION)
Table 83 ASIA: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2013–2020 ($BILLION)
Table 84 ROW: BIOMARKERS MARKET SIZE, BY PRODUCT, 2013–2020 ($BILLION)
Table 85 ROW: BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 ($BILLION)
Table 86 ROW: EFFICACY BIOMARKERS MARKET SIZE, BY TYPE, 2013–2020 ($BILLION)
Table 87 ROW: BIOMARKERS MARKET SIZE, BY APPLICATION, 2013–2020 ($BILLION)
Table 88 ROW: BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2013–2020 ($BILLION)
Table 89 MARKET DEVELOPMENTS BETWEEN JANUARY 2012 AND MAY 2015
Table 90 ACQUISITION, 2012–2015
Table 91 AGREEMENT, COLLABORATIONS, EXPANSION, JOINT VENTURES AND PARTNERSHIPS, 2012–2015
Table 92 NEW PRODUCT AND SERVICE LAUNCHES, 2012–2015
Table 93 OTHER DEVELOPMENTS, 2012–2015

LIST OF FIGURES

Figure 1 BIOMARKERS MARKET
Figure 2 RESEARCH DESIGN
Figure 3 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
Figure 4 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
Figure 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 6 DATA TRIANGULATION METHODOLOGY
Figure 7 BIOMARKERS MARKET SIZE, BY PRODUCT, 2015 VS. 2020 ($BILLION)
Figure 8 BIOMARKERS MARKET SIZE, BY TYPE, 2015 VS. 2020 ($BILLION)
Figure 9 BIOMARKERS MARKET SIZE, BY APPLICATION, 2015 VS. 2020 ($BILLION)
Figure 10 BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2015 VS. 2020 ($BILLION)
Figure 11 BIOMARKERS MARKET SIZE, BY REGION, 2015 VS. 2020 ($BILLION)
Figure 12 GLOBAL BIOMARKERS MARKET TO WITNESS HIGH GROWTH DURING THE FORECAST PERIOD
Figure 13 CONSUMABLES SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2015
Figure 14 ASIA TO WITNESS HIGHEST GROWTH RATE IN THE FORECAST PERIOD
Figure 15 ASIAN MARKET SHOWS LUCRATIVE GROWTH OPPORTUNITIES
Figure 16 BIOMARKERS MARKET: BY PRODUCT
Figure 17 BIOMARKERS MARKET: BY TYPE
Figure 18 BIOMARKERS MARKET: BY APPLICATION
Figure 19 BIOMARKERS MARKET: BY DISEASE INDICATION
Figure 20 BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
Figure 21 INCREASING HEALTHCARE EXPENDITURE IS THE MOST IMPORTANT DRIVER FOR THE BIOMARKERS MARKET
Figure 22 INCREASING R&D INVESTMENTS BOOSTING GROWTH IN THE BIOMARKERS MARKET
Figure 23 BIOMARKERS MARKET, BY PRODUCT
Figure 24 CONSUMABLES SEGMENT TO COMMAND THE LARGEST SHARE OF THE BIOMARKERS MARKET IN 2015
Figure 25 NORTH AMERICA WILL BE THE LARGEST REGIONAL SEGMENT OF THE CONSUMABLES MARKET IN 2015
Figure 26 ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT OF THE BIOMARKER SERVICES MARKET BETWEEN 2015 AND 2020
Figure 27 NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE BIOMARKER SOFTWARE MARKET IN 2015
Figure 28 BIOMARKERS MARKET, BY TYPE
Figure 29 SAFETY BIOMARKERS TO COMMAND THE LARGEST SHARE OF THE BIOMARKERS MARKET IN 2015
Figure 30 ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT FOR SAFETY BIOMARKERS IN THE FORECAST PERIOD
Figure 31 EFFICACY BIOMARKERS MARKET, BY TYPE
Figure 32 PREDICTIVE BIOMARKERS SEGMENT TO COMMAND THE LARGEST SHARE OF THE EFFICACY BIOMARKERS MARKET IN 2015
Figure 33 NORTH AMERICA TO BE THE LARGEST REGIONAL SEGMENT FOR EFFICACY BIOMARKERS IN 2015
Figure 34 ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT OF THE PREDICTIVE BIOMARKERS MARKET BETWEEN 2015 AND 2020
Figure 35 NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE SURROGATE BIOMARKERS MARKET IN 2015
Figure 36 ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT FOR PHARMACODYNAMIC BIOMARKERS IN THE FORECAST PERIOD
Figure 37 NORTH AMERICA TO BE THE LARGEST REGIONAL SEGMENT OF THE PROGNOSTIC BIOMARKERS MARKET IN 2015
Figure 38 ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT FOR VALIDATION BIOMARKERS BETWEEN 2015 AND 2020
Figure 39 BIOMARKERS MARKET, BY APPLICATION
Figure 40 DIAGNOSTICS DEVELOPMENT TO COMMAND THE LARGEST SHARE OF THE BIOMARKERS MARKET IN 2015
Figure 41 NORTH AMERICA IS EXPECTED TO BE THE LARGEST REGIONAL MARKET FOR DIAGNOSTICS DEVELOPMENT
Figure 42 ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT IN THE DRUG DISCOVERY AND DEVELOPMENT MARKET
Figure 43 NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE PERSONALIZED MEDICINE MARKET IN 2015
Figure 44 ASIA IS THE FASTEST-GROWING REGIONAL SEGMENT FOR DISEASE RISK ASSESSMENT
Figure 45 NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE BIOMARKERS MARKET FOR OTHER APPLICATIONS
Figure 46 BIOMARKERS MARKET, BY DISEASE INDICATION
Figure 47 CANCER WILL BE THE LARGEST DISEASE INDICATION SEGMENT OF THE BIOMARKERS MARKET IN 2015
Figure 48 NORTH AMERICA TO BE THE LARGEST REGIONAL SEGMENT FOR BIOMARKERS FOR CARDIOVASCULAR DISORDERS IN 2015
Figure 49 ASIAN BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS TO GROW AT THE HIGHEST RATE
Figure 50 NORTH AMERICA TO COMMAND THE LARGEST SHARE OF THE BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS IN 2015
Figure 51 ASIA TO BE THE FASTEST-GROWING REGIONAL SEGMENT OF THE BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS
Figure 52 GLOBAL ECONOMIC INDICATORS (2003–2012)
Figure 53 BIOMARKERS MARKET SIZE AND GROWTH RATE, BY REGION, 2015-2020
Figure 54 BIOMARKERS MARKET IN ASIA TO WITNESS HIGHEST GROWTH RATE FROM 2015 TO 2020
Figure 55 NORTH AMERICA: ECONOMIC INDICATORS (2003–2012)
Figure 56 NORTH AMERICA: MARKET SNAPSHOT
Figure 57 CONSUMABLES IS ESTIMATED TO BE THE LARGEST PRODUCT SEGMENT OF THE NORTH AMERICAN BIOMARKERS MARKET IN 2015
Figure 58 SAFETY BIOMARKERS TO COMMAND THE LARGEST SHARE OF THE NORTH AMERICAN BIOMARKERS MARKET BY 2020
Figure 59 PREDICTIVE BIOMARKERS SEGMENT WILL CONTINUE TO DOMINATE THE EFFICACY BIOMARKERS MARKET IN NORTH AMERICA
Figure 60 DIAGNOSTICS DEVELOPMENT SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICAN BIOMARKERS APPLICATIONS MARKET IN 2015
Figure 61 CANCER TO ACCOUNT FOR THE LARGEST DISEASE INDICATION SEGMENT OF THE NORTH AMERICAN BIOMARKERS MARKET IN 2015
Figure 62 U.S.: ECONOMIC INDICATORS (2003–2012)
Figure 63 CONSUMABLES TO ACCOUNT FOR THE LARGEST SHARE OF THE U.S. BIOMARKERS PRODUCTS MARKET IN 2015
Figure 64 SAFETY BIOMARKERS TO FORM THE LARGEST SEGMENT OF THE U.S. BIOMARKERS MARKET IN 2015
Figure 65 PREDICTIVE BIOMARKERS WILL CONTINUE TO DOMINATE THE EFFICACY BIOMARKERS MARKET IN THE U.S.
Figure 66 DIAGNOSTICS DEVELOPMENT TO COMMAND THE LARGEST SHARE OF THE U.S. BIOMARKERS APPLICATIONS MARKET IN 2015
Figure 67 CANCER TO FORM THE LARGEST DISEASE INDICATION SEGMENT OF THE U.S. BIOMARKERS MARKET IN 2015
Figure 68 CANADA: ECONOMIC INDICATORS (2003-2012)
Figure 69 CONSUMABLES TO ACCOUNT FOR THE LARGEST SEGMENT OF THE CANADIAN BIOMARKERS PRODUCTS MARKET IN 2015
Figure 70 SAFETY BIOMARKERS TO DOMINATE THE CANADIAN BIOMARKERS MARKET BY 2020
Figure 71 PREDICTIVE BIOMARKERS WILL CONTINUE TO DOMINATE THE CANADIAN EFFICACY BIOMARKERS MARKET
Figure 72 DIAGNOSTICS DEVELOPMENT SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE CANADIAN BIOMARKERS MARKET IN 2015
Figure 73 CANCER TO FORM THE LARGEST DISEASE INDICATION SEGMENT OF THE CANADIAN BIOMARKERS MARKET IN 2015
Figure 74 EUROPE: ECONOMIC INDICATORS (2003–2012)
Figure 75 CONSUMABLES IS ESTIMATED TO BE THE LARGEST PRODUCT SEGMENT OF THE EUROPEAN BIOMARKERS MARKET IN 2015
Figure 76 SAFETY BIOMARKERS TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPEAN BIOMARKERS MARKET IN 2015
Figure 77 PREDICTIVE BIOMARKERS TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPEAN EFFICACY BIOMARKERS MARKET IN 2015
Figure 78 DIAGNOSTICS DEVELOPMENT SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPEAN BIOMARKERS APPLICATIONS SEGMENT IN 2015
Figure 79 CANCER TO FORM THE LARGEST DISEASE INDICATION SEGMENT OF THE EUROPEAN BIOMARKERS MARKET IN 2015
Figure 80 ASIA: ECONOMIC INDICATORS (2003–2012)
Figure 81 ASIA: MARKET SNAPSHOT
Figure 82 CONSUMABLES IS ESTIMATED TO BE THE LARGEST SEGMENT OF THE ASIAN BIOMARKERS MARKET IN 2015
Figure 83 SAFETY BIOMARKERS TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIAN BIOMARKERS MARKET IN 2015
Figure 84 PREDICTIVE BIOMARKERS TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIAN EFFICACY BIOMARKERS MARKET IN 2015
Figure 85 DIAGNOSTICS DEVELOPMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIAN BIOMARKERS APPLICATIONS MARKET IN 2015
Figure 86 CANCER TO FORM THE LARGEST DISEASE INDICATION SEGMENT OF THE ASIAN BIOMARKERS MARKET IN 2015
Figure 87 REST OF THE WORLD: ECONOMIC INDICATORS (2003–2012)
Figure 88 CONSUMABLES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ROW BIOMARKERS PRODUCTS MARKET IN 2015
Figure 89 SAFETY BIOMARKERS TO ACCOUNT FOR THE LARGEST SHARE OF THE ROW BIOMARKERS MARKET IN 2015
Figure 90 PREDICTIVE BIOMARKERS TO ACCOUNT FOR THE LARGEST SHARE OF THE ROW EFFICACY BIOMARKERS MARKET IN 2015
Figure 91 DIAGNOSTICS DEVELOPMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE ROW BIOMARKERS APPLICATIONS MARKET IN 2015
Figure 92 CANCER TO FORM THE LARGEST DISEASE INDICATION SEGMENT OF THE ROW BIOMARKERS MARKET IN 2015
Figure 93 KEY DEVELOPMENTS WITHIN THE OVERALL BIOMARKERS MARKET, 2012 TO 2015
Figure 94 BIOMARKERS MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2014
Figure 95 FINANCIAL PERFORMANCE OF LEADING MARKET PLAYERS
Figure 96 COMPANY SNAPSHOT: QIAGEN N.V.
Figure 97 COMPANY SNAPSHOT: PERKINELMER, INC.
Figure 98 COMPANY SNAPSHOT: MERCK & CO, INC.
Figure 99 COMPANY SNAPSHOT: BIO-RAD LABORATORIES, INC.
Figure 100 COMPANY SNAPSHOT: ENZO BIOCHEM, INC.
Figure 101 COMPANY SNAPSHOT: EKF DIAGNOSTICS HOLDINGS, INC.
Skip to top


Ask Your Question

Biomarkers Market by Product (Consumables, Services), Type (Predictive, Pharmacodynamic, Safety), Application (Diagnostics, Drug Discovery, Personalized Medicine) & by Disease Indication (Cardiovascular, Immunological) - Global Forecast to 2020
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: